Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
Roswell Park Cancer Institute
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
70High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07489066CT.gov Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC | — | Recruiting | — | — | — |
NCT06968195CT.gov Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma | — | Suspended | — | — | — |
NCT07500220CT.gov Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC | — | Recruiting | — | — | — |
NCT07412054CT.gov Lenvatinib and Pembrolizumab With or Without BCAA in Unresectable HCC | — | Not Yet Recruiting | — | — | — |
NCT07242417CT.gov TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT07223424CT.gov Patient Preference for Subcutaneous vs. Intravenous Immune Therapy | — | Recruiting | — | — | — |
NCT06690281CT.gov A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies | — | Withdrawn | — | — | — |
NCT06902389CT.gov A Clinical Study of Multi-target Hi-TCR-T Cells in the Treatment of Advanced Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT07157969CT.gov ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC | — | Recruiting | — | — | — |
NCT06600321CT.gov A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma | — | Recruiting | — | — | — |
Show 88 more trialsShow fewer
NCT06652243CT.gov Clinical Study of SN301A Injection in the Treatment of Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT06641453CT.gov CAR-T Cell Therapy Targeting GPC3 in Patients with Advanced GPC3-Positive Hepatocellular Carcinoma | — | Not Yet Recruiting | — | — | — |
NCT06515314CT.gov HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors | — | Recruiting | — | — | — |
NCT06389422CT.gov Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis | — | Recruiting | — | — | — |
NCT06205706CT.gov BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT05824975CT.gov A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) | — | Recruiting | — | — | — |
NCT05440708CT.gov A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT05438420CT.gov Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT05926726CT.gov GPC3-directed CAR-T in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT05468359CT.gov Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients | — | Recruiting | — | — | — |
NCT05120271CT.gov BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT05208762CT.gov A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05581004CT.gov A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT05620134CT.gov Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | — | Active Not Recruiting | — | — | — |
NCT05185739CT.gov Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC) | — | Recruiting | — | — | — |
NCT04897321CT.gov B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) | — | Recruiting | — | — | — |
NCT05256381CT.gov A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors | — | Terminated | — | — | — |
NCT05339581CT.gov IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver Transplantation | — | Unknown | — | — | — |
NCT05101629CT.gov Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy | — | Completed | — | — | — |
NCT05070247CT.gov A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors | — | Terminated | — | — | — |
NCT05269381CT.gov Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06144385CT.gov A Phase 1, Single-arm, Open-label, Dose-escalation Study of JWATM204 as T Cell-targeted Immunotherapy in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT05220722CT.gov Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors | — | Terminated | — | — | — |
NCT05323201CT.gov Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer | — | Recruiting | — | — | — |
NCT05104567CT.gov A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203) | — | Completed | — | — | — |
NCT05003895CT.gov GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies | — | Recruiting | — | — | — |
NCT05075993CT.gov Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT05091346CT.gov A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors | — | Completed | — | — | — |
NCT04777708CT.gov BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer | — | Terminated | — | — | — |
NCT05028933CT.gov IMC001 for Clinical Research on Advanced Digestive System Malignancies | — | Unknown | — | — | — |
NCT05007106CT.gov MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) | — | Completed | — | — | — |
NCT04828486CT.gov Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer | — | Completed | — | — | — |
NCT04787042CT.gov Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 | — | Recruiting | — | — | — |
NCT04442581CT.gov Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer | — | Terminated | — | — | — |
NCT04740307CT.gov Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004) | — | Completed | — | — | — |
NCT04696055CT.gov Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors | — | Completed | — | — | — |
NCT04660929CT.gov CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | — | Unknown | — | — | — |
NCT04282044CT.gov Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies | — | Recruiting | — | — | — |
NCT04222972CT.gov A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) | — | Terminated | — | — | — |
NCT04483778CT.gov B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | — | Active Not Recruiting | — | — | — |
NCT04246177CT.gov Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012) | — | Completed | — | — | — |
NCT04374877CT.gov Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT04317248CT.gov "Cocktail" Therapy for Hepatitis B Related Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT04251117CT.gov GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC | — | Active Not Recruiting | — | — | — |
NCT04244552CT.gov A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | — | Terminated | — | — | — |
NCT04093648CT.gov T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR) | — | Withdrawn | — | — | — |
NCT04224480CT.gov Longitudinal Immune-phenotyping of HCC Following MK-3475 | — | Unknown | — | — | — |
NCT04099277CT.gov A Study of LY3435151 in Participants With Solid Tumors | — | Terminated | — | — | — |
NCT03884751CT.gov Chimeric Antigen Receptor T Cells Targeting Glypican-3 | — | Completed | — | — | — |
NCT04060342CT.gov GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | — | Terminated | — | — | — |
NCT03971747CT.gov AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT03980288CT.gov 4th Generation Chimeric Antigen Receptor T Cells Targeting Glypican-3 | — | Completed | — | — | — |
NCT04234113CT.gov Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors | — | Terminated | — | — | — |
NCT03867084CT.gov Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937) | — | Completed | — | — | — |
NCT03753659CT.gov IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC) | — | Completed | — | — | — |
NCT02905188CT.gov Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR) | — | Completed | — | — | — |
NCT03859128CT.gov Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical Resection | — | Unknown | — | — | — |
NCT03655002CT.gov IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer | — | Active Not Recruiting | — | — | — |
NCT03841110CT.gov FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT03713593CT.gov Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002) | — | Completed | — | — | — |
NCT03836352CT.gov Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03511222CT.gov Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors | — | Terminated | — | — | — |
NCT03347292CT.gov Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC | — | Completed | — | — | — |
NCT03563170CT.gov QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine | — | Withdrawn | — | — | — |
NCT03419481CT.gov Pembrolizumab in Hepatocellular Carcinoma | — | Active Not Recruiting | — | — | — |
NCT03519997CT.gov A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma | — | Active Not Recruiting | — | — | — |
NCT03316872CT.gov Study of Pembrolizumab and Radiotherapy in Liver Cancer | — | Terminated | — | — | — |
NCT03397654CT.gov Study of Pembrolizumab Following TACE in Primary Liver Carcinoma | — | Completed | — | — | — |
NCT03319459CT.gov FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT03302403CT.gov Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors | — | Unknown | — | — | — |
NCT03163992CT.gov Pembrolizumab in Advanced Hepatocellular Carcinoma as Second-line Treatment After Failure of Sorafenib | — | Completed | — | — | — |
NCT03211416CT.gov Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer | — | Completed | — | — | — |
NCT03337841CT.gov Pembrolizumab as Neoadjuvant Treatment in HCC | — | Unknown | — | — | — |
NCT03203005CT.gov IMA970A Plus CV8102 in Very Early, Early and Intermediate Stage Hepatocellular Carcinoma Patients | — | Completed | — | — | — |
NCT03084380CT.gov Anti-GPC3 CAR-T for Treating GPC3-positive Advanced Hepatocellular Carcinoma (HCC) | — | Unknown | — | — | — |
NCT03062358CT.gov Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394) | — | Completed | — | — | — |
NCT03099564CT.gov Pembrolizumab Plus Y90 Radioembolization in HCC Subjects | — | Unknown | — | — | — |
NCT03146234CT.gov CAR-GPC3 T Cells in Patients With Refractory Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT02940496CT.gov Pembrolizumab (MK-3475) in Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT02432963CT.gov Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | — | Active Not Recruiting | — | — | — |
NCT02702414CT.gov Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224) | — | Completed | — | — | — |
NCT02702401CT.gov Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240) | — | Completed | — | — | — |
NCT02658019CT.gov Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT02595866CT.gov Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer | — | Completed | — | — | — |
NCT02702960CT.gov Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC) | — | Withdrawn | — | — | — |
NCT02509507CT.gov Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611 | — | Completed | — | — | — |
NCT01967823CT.gov T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer | — | Completed | — | — | — |
NCT00390195CT.gov Randomized Phase I/II of RAD001 in Advanced Hepatocellular Carcinoma (HCC) | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hepatocellular Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cyclophosphamide (this asset) | Roswell Park Cancer Institute | P3 | BB · 69 |
| Adefovir | Bukwang Pharmaceutical | P4 | BBB |
| Huaier Granule | Tongji Hospital | P4 | BBB |
| Fluorouracilum | Li Qiang | P4 | BBB |
| Oxaliplatin | Li Qiang | P4 | BBB |
| Theprubicin | RWTH Aachen University | P4 | BB |
| Adriamycin | VA Office of Research and Development | P4 | BB |
| nrt6003 | Second Affiliated Hospital of Guangzhou Medical University | P3 | BB |
| Epirubicin | Fudan University | P4 | BB |
+42 more in the Hepatocellular Carcinoma cohort
Other indications for Cyclophosphamide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| Mycosis Fungoides | — | P4 | BBB · 78 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cyclophosphamide in Hepatocellular Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 9, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cyclophosphamide-hepatocellular-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →